Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines
🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation SYK inhibitor, called cevidoplenib. The South Korean biotech is eligible ...
June 1, 2026 10:39 AM EDT News Briefing Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines ENDPOINTS 🪪 Agios licenses Oscotec’s immune thrombocytopenia drug: Agios is paying $25 million upfront for exclusive global rights to Oscotec’s next-generation … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that